Clinical Trial Update: Regulatory Hycamtin(Oral) PMS

View source ↗

Summary

This document reports completion of a post-marketing surveillance study evaluating the oral formulation of Hycamtin (topotecan) for small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Hycamtin (Topotecan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Small Cell | Status: COMPLETED